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Objectives: To estimate hospital costs for cardiovascular (CV) events and revas-
cularisation procedure associated with inpatient care analysing data from 14 
acute care Spanish hospitals (RECH network), and to compare these costs with 
national tariffs for the corresponding diagnosis-related groups (DRGs) for similar 
events. MethOds: A retrospective study (period: 2009-2013) collecting data from 
discharge records (~1,050,000) from adult patients was performed. Mean costs and 
length of stay per patient were collected for non-fatal events according primary 
diagnosis (CIE9-MC) including myocardial infarction (MI), unstable angina, conges-
tive heart failure (CHF) with hospitalization, stroke, revascularisation procedures 
and CV death. Average costs per patient for non-fatal CV events, revascularisa-
tion procedures and CV death were estimated according per-patient cost informa-
tion from the RECH database, that included both AP-DRG and APR-DRG groupers 
which are used for alternative cost comparisons. Subsequently, observed costs per 
DRG were compared with national DRG tariffs. All costs were expressed in € for 
the year 2014. Results: Mean costs based on patient-level data from the RECH 
network for non-fatal acute MI, unstable angina, CHF with hospitalisation, stroke 
and revascularisation procedures were € 8,669, € 3,162, € 3,353, € 4,644 and € 10,159 
respectively. Average length of stay for non-fatal events ranged between 5.3 and 
10.2 hospitalisation days and between 6.4 and 19.5 for revascularisation proce-
dures. The comparison of costs from the RECH network with national tariffs for 
AP-DRGs, showed differences of € 57 for revascularisation procedures, € 298 for CHF 
with hospitalisation, € 1,096 for unstable angina, € 1,316 for stroke, € 3,794 for CV 
death and € 4,249 for acute MI. cOnclusiOns: Average per-patient costs based 
on discharge records from the RECH network for CV events and revascularisation 
procedures were higher than the national tariffs for AP-DRGs of similar events and 
procedures. These differences may result in important economic consequences for 
the Spanish health system.
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Objectives: To understand the hospitalization expenses and the cost-sharing situ-
ation among Chinese stroke patients covered by Urban Employee Basic Medical 
Insurance (UEBMI). MethOds: The data are derived from China Health Insurance 
Research Association’s (CHIRA) Survey (2012). The survey adopts the systematic 
sampling method to draw samples from the inpatients with UEBMI of the previous 
year and gets details about their disease diagnosis, medical service utilization and 
expenses. The sampling rate varies with different regions with an average rate of 
2%~10%. SPSS17.0 is used to conduct the statistical analysis. Results: A total of 
22,765 stroke patients were obtained from the sampling. The proportion of male 
stroke patients (59%) was obviously higher than female patients (41%). As for age, 
stroke patients aged 70~79 accounted for the highest ratio (32%), followed by 60~69 
(27%) and 50~59 (19%). The average LOS of stroke patients was 16.2 days, which 
was longer in the tier-3 hospitals (17.4 days) than in the tier-2 ones (15.3 days). The 
average hospitalization expenses were 8,598 yuan, the average drug expenses were 
5,049 yuan, accounting for about 59% of the total hospitalization expenses. Average 
costs of the tier-3 hospitals were higher than other hospitals, with the average hos-
pitalization expenses being 13,381 yuan and the average drug expenses being 7,318 
yuan (occupying about 55% of the hospitalization expenses). The UEBMI payment 
accounted for about 69% of the total hospitalization expenses and about 79% of the 
drug cost. Patients’ co-payment proportion was higher in tier-3 hospitals than other 
ones. cOnclusiOns: Chinese stroke patients are mostly over 50 years old, with 
more male patients than female patients. The average hospitalization expenses 
are 8,598 yuan and payer’s payment proportion is lower than 70%. Expenses of the 
tier-3 hospitals are apparently higher than other hospitals. Medicine charges take 
up more than half of the hospitalization expenses.
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Objectives: Comparative evaluation of the cost effectiveness of treatment of 
patients with acute coronary syndrome without ST segment elevation (ACS) effi-
ciency using two therapy schemes in Ukraine. MethOds: “The cost-efficiency” 
method was used to carrying out the study. Analysis was based on the results of 
opened international multicenter randomized trial of efficiency of tiazotic acid 
morpholinium salt in ACS patients. The clinical trial involved 100 patients rand-
omized into main and control groups (each group contained 50 patients). Standard 
therapy (narcotic analgesics, seduction drugs, nitrates, β -blockers, anticoagulants, 
antithrombotic drugs, calcium channel blockers, ACEs, sartans and statins) and 
injections of tiazotic acid morpholinium salt were administrated in the main group; 
only standard therapy was administrated in the control group. Treatment of patients 
was carried out during 14 days. For determining the cost of a course therapy for 
a patient with craniocerebral injury only the direct costs in the studied regimens 
were taken into account. Drugs prices were taken from Morion’s information system 
(May, 2015). As an indicator of the effectiveness after treatment were considered the 
following: 5 % increase in ejection fraction, 10 % decreasing in myocardial ischemia 
duration (based on Holter ECG monitoring), 10 % decrease in quantity of ventricu-
lar arrhythmia episodes (based on ECG Holter monitoring). Results: The treat-
ment efficiency in main group patients was 84 % and 54 % in controls. Treatment 
during 2012, 2013 and 2014. Two health regions of Spain (Comunitat Valenciana with 
4.949.219 inhabitants and Extremadurawith 1.093.587. Total population: 6,042,806) 
where compared. In order to make it comparable, DDDs where measured as num-
bers of DDDs/1000 inhabitants/day (DHDs). Results: Atorvastatin and simvastatin 
are the most prescribed statins in both regions. However in Extremadura, the pro-
portion of DHD of these two chemical substances over the total amount of statins 
has decreased from 70.13% in 2012 to 68.00% in 2014. By contrast, in Comunitat 
Valenciana the proportion has increased from 73.45% in 2012 to 82.40% in 2014. In 
both regions the number of DHD of statins increases (in Extremadura from 106.75 
DHD in 2012 to 120.14 DHD in 2014; in Comunitat Valenciana from 98.08 DHD in 
2012 to 104.15 DHD in 2014). However, in Comunitat Valenciana the increase in 
consumption has not resulted in increased drug spending but in a drop of 7.41%. 
By contrast, Extremadura’s pharmaceutical expenditure of statins has increased 
a 17.62%. cOnclusiOns: In the region that did not introduced the algorithm for 
statins into the electronic prescribing tool, less cost effective statins are gaining 
market share. In the region which introduced the prescription algorithm, although 
statin use increases, its pharmaceutical expenditure decreases, resulting in savings 
that can be spent elsewhere medication.
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Objectives: The Prescription e-Protocols for Medicines (PePM), which devel-
oped under the coordination of the Athens Medical Society (AMS), are to be used 
by all physicians as an aid in prescription and to set out a framework of “good 
medical practice”, based on the up-to-day clinical evidence. To make the use of 
prescription protocols efficient, the main objective was to transform the proto-
col’s information into machine processable format, integrate with the national 
e-prescription system and measure the cost impact. MethOds: AMS has already 
developed prescription e-protocols for seven therapeutic categories (20 proto-
cols). The representation model of PePM includes five levels of information: gen-
eral information, treatment steps and sub-conditions according the use of risk 
assessment algorithms, treatment at active substance level and at product level. 
The process of prescribing according to PePM, includes: select protocol accord-
ing to ICD10 diagnoses, insert input parameters, select medication and finalize 
prescription. Their cost impact was measured by comparing the periods of using 
the protocols with the relevant period not using them on the Greek National 
ePrescription system. Results: Using the example of the dyslipidemia proto-
col and the stratification of the population according to heart score algorithm, 
comparing statins use, between two periods (09-11/2013 vs 09-11/2014) had an 
overall reduction of the cost by 15.85%. Reduction of the second step statins’ 
cost: atorvastatin -17.16%, rosuvastatin -3.93%, ezetimibe -29.83%, ezetimibe/
simvastatin -12.38%. cOnclusiOns: The recent economic crisis and subse-
quent public expenditure cuts have slowed the rate of heath expenditure growth. 
Pharmaceutical expenditure has even decreased as it has been identified as one 
of the main areas of public spending cuts. Our proposal concerns that suitable 
prescribing guidelines with the integration on the ePrescription system ensures 
patient access to quality health service and containing costs according to real 
health needs and in alignment with evidence-based medicine principles.
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Objectives: To estimate monthly medical costs of controlled and inadequately-
controlled non-valvular atrial fibrillation (NVAF) patients treated with Vitamin K 
antagonists (VKA). MethOds: Retrospective cohort study of NVAF patients newly 
initiating VKA between January 2009 and December 2014 using a database from 
a healthcare provider from Badalona (Spain) (120,000 inhabitants). We followed 
patients from first VKA treatment until study end, leaving database, VKA discontin-
uation, or death; calculated proportion of patients with adequate anticoagulation 
(time in therapeutic range (TTR) ≥ 60% using target international normalized ratio 
(INR) 2-3) over 12 months post-initiation; and estimated monthly mean healthcare 
costs linked to NVAF for controlled and inadequately-controlled patients, adopting 
a payer perspective. Results: The study included 1,144 patients (median(IQR) 
follow-up 28.8 (14.2–43.1) months) with 67.1% well-controlled patients over 0-12 
month period. At baseline, for controlled and inadequately-controlled patients 
respectively, mean(SD) age was 74.3(10.3) and 74.3(10.7) years and 48.2% and 
54.3% were female. Mean Charlson index was 0.9(1.4) and 1.1(1.4), (p:0.025), and 
CHA2DS2-VASc scores were 2.7(1.6) and 2.9(1.6) (p:0.038) for controlled and inad-
equately-controlled patients, respectively. Mean(SD) monthly medical costs were 
€ 80.3(174.8) and € 143.6(656.6) respectively, being 1.8-fold higher for inadequately-
controlled patients (p:0.013). The largest cost components were general practi-
tioner visits, hospitalizations, and specialist visits. INR testing was also more 
costly in inadequately-controlled patients (mean monthly INR cost(SD) € 2.3(1.1) 
versus € 2.7(1. 9) p:< 0.001 for controlled and inadequately-controlled patients 
respectively) and accounted for 1.9% and 2.9% of costs, respectively. Other time 
periods assessed gave qualitatively similar results. cOnclusiOns: In this study, 
1/3 of NVAF patients treated with VKAs were inadequately controlled. These 
patients had a higher baseline stroke risk and comorbidity index and generated 
higher direct medical costs associated with NVAF compared to controlled patients. 
In this context, future research could address the medical costs associated with 
novel anticoagulants in NVAF patients.
